|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for STIM1 |
 Gene summary |
| Basic gene Info. | Gene symbol | STIM1 |
| Gene name | stromal interaction molecule 1 | |
| Synonyms | D11S4896E|GOK|IMD10|STRMK|TAM|TAM1 | |
| Cytomap | UCSC genome browser: 11p15.5 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001277961.1, NM_001277962.1,NM_003156.3, | |
| Description | - | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 605921 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000167323 | ||
| HPRD : 05803 | ||
| Vega : OTTHUMG00000133360 | ||
| Protein | UniProt: Q13586 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_STIM1 | |
| BioGPS: 6786 | ||
| Pathway | NCI Pathway Interaction Database: STIM1 | |
| KEGG: STIM1 | ||
| REACTOME: STIM1 | ||
| Pathway Commons: STIM1 | ||
| Context | iHOP: STIM1 | |
| ligand binding site mutation search in PubMed: STIM1 | ||
| UCL Cancer Institute: STIM1 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0005513 | detection of calcium ion | 16005298 | GO:0032237 | activation of store-operated calcium channel activity | 16005298 | GO:0051924 | regulation of calcium ion transport | 16005298 |
| Top |
| Ligand binding site mutations for STIM1 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | Y362 | Y361C | COAD | 1 | L351 | W350L | LUAD | 1 | E87 | E87Q | LUAD | 1 | A343 | A343V | SKCM | 1 | R6 | V5I | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for STIM1 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R6 | V5I | 0.23964216 | Y362 | Y361C | -1.4790617 | E87 | E87Q | -0.96067209 | A343 | A343V | -0.38550657 | L351 | W350L | -0.37110396 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for STIM1 from PDB |
| Top |
| Differential gene expression and gene-gene network for STIM1 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for STIM1 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0410207 | MYOPATHY, TUBULAR AGGREGATE | 3 | Biomarker, GeneticVariation |
| umls:C2748557 | Immune dysfunction with T-cell inactivation due to calcium entry defect 2 | 2 | Biomarker, GeneticVariation |
| umls:C1861451 | Stormorken Syndrome | 2 | Biomarker, GeneticVariation |
| umls:C0020538 | Hypertension | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for STIM1 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of STIM1 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (GLY,SER,GLU,LEU,ASN,GLU,LEU,ALA,GLU,PHE,ALA,ARG,LEU,GLN,ASP,GLN,LEU,ASP,HIS,ARG,GLY,ASP,HIS) | 2mak | A | A343 L351 Y362 | III | Peptide ligand (GLY,SER,GLU,LEU,ASN,GLU,LEU,ALA,GLU,PHE,ALA,ARG,LEU,GLN,ASP,GLN,LEU,ASP,HIS,ARG,GLY,ASP,HIS) | 2mak | C | A343 L351 Y362 | CA | CALCIUM(2+) | 2k60 | A | E87 | III | Peptide ligand (GLY,SER,GLU,LEU,ASN,GLU,LEU,ALA,GLU,PHE,ALA,ARG,LEU,GLN,ASP,GLN,LEU,ASP,HIS,ARG,GLY,ASP,HIS) | 2mak | A | Y362 | III | Peptide ligand (GLY,SER,GLU,LEU,ASN,GLU,LEU,ALA,GLU,PHE,ALA,ARG,LEU,GLN,ASP,GLN,LEU,ASP,HIS,ARG,GLY,ASP,HIS) | 2mak | C | Y362 |
| Top |
| Conservation information for LBS of STIM1 |
| Multiple alignments for Q13586 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |